Cédric Rossi , Guillaume Manson , Amira Marouf , Aurélie Cabannes-Hamy , Emmanuelle Nicolas-Virelizier , Marie Maerevoet , Marion Alcantara , Lysiane Molina , Antony Ceraulo , Marilyne Poirée , Jean Galtier , Nadia Diop , Caroline Delette , Amandine Segot , Sydney Dubois , Agathe Waultier , Sophie Bernard , Robin Noël , Stéphanie Guidez , Milena Kohn , Hervé Ghesquières
{"title":"典型霍奇金淋巴瘤:LYSA 实用指南","authors":"Cédric Rossi , Guillaume Manson , Amira Marouf , Aurélie Cabannes-Hamy , Emmanuelle Nicolas-Virelizier , Marie Maerevoet , Marion Alcantara , Lysiane Molina , Antony Ceraulo , Marilyne Poirée , Jean Galtier , Nadia Diop , Caroline Delette , Amandine Segot , Sydney Dubois , Agathe Waultier , Sophie Bernard , Robin Noël , Stéphanie Guidez , Milena Kohn , Hervé Ghesquières","doi":"10.1016/j.ejca.2024.115073","DOIUrl":null,"url":null,"abstract":"<div><div>Classic Hodgkin lymphoma (HL) is a distinct entity among hematological malignancies of B-cell origin. It is characterized by its unique histopathological features and generally favorable prognosis. Over the years, advancements in understanding its pathogenesis, coupled with refined diagnostic and evaluation modalities, as well as therapeutic strategies, have significantly transformed the landscape of HL management. In this article, we present a comprehensive set of recommendations for the management of HL, encompassing various aspects of diagnosis, risk stratification, evaluation, and treatment. These recommendations are based on the latest evidence-based guidelines, expert consensus opinions, and clinical trial data, aiming to provide clinicians with a practical framework for delivering optimal care to patients with HL.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":null,"pages":null},"PeriodicalIF":7.6000,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Classic Hodgkin Lymphoma: The LYSA pragmatic guidelines\",\"authors\":\"Cédric Rossi , Guillaume Manson , Amira Marouf , Aurélie Cabannes-Hamy , Emmanuelle Nicolas-Virelizier , Marie Maerevoet , Marion Alcantara , Lysiane Molina , Antony Ceraulo , Marilyne Poirée , Jean Galtier , Nadia Diop , Caroline Delette , Amandine Segot , Sydney Dubois , Agathe Waultier , Sophie Bernard , Robin Noël , Stéphanie Guidez , Milena Kohn , Hervé Ghesquières\",\"doi\":\"10.1016/j.ejca.2024.115073\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Classic Hodgkin lymphoma (HL) is a distinct entity among hematological malignancies of B-cell origin. It is characterized by its unique histopathological features and generally favorable prognosis. Over the years, advancements in understanding its pathogenesis, coupled with refined diagnostic and evaluation modalities, as well as therapeutic strategies, have significantly transformed the landscape of HL management. In this article, we present a comprehensive set of recommendations for the management of HL, encompassing various aspects of diagnosis, risk stratification, evaluation, and treatment. These recommendations are based on the latest evidence-based guidelines, expert consensus opinions, and clinical trial data, aiming to provide clinicians with a practical framework for delivering optimal care to patients with HL.</div></div>\",\"PeriodicalId\":11980,\"journal\":{\"name\":\"European Journal of Cancer\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":7.6000,\"publicationDate\":\"2024-10-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Journal of Cancer\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0959804924012048\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Cancer","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0959804924012048","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
经典霍奇金淋巴瘤(HL)是 B 细胞来源血液恶性肿瘤中的一种独特类型。它具有独特的组织病理学特征,预后一般良好。多年来,随着对其发病机制认识的不断深入、诊断和评估方法的不断完善以及治疗策略的不断改进,HL 的治疗格局发生了显著变化。在本文中,我们为 HL 的治疗提出了一套全面的建议,包括诊断、风险分层、评估和治疗等各个方面。这些建议基于最新的循证指南、专家共识意见和临床试验数据,旨在为临床医生提供一个切实可行的框架,为 HL 患者提供最佳治疗。
Classic Hodgkin Lymphoma: The LYSA pragmatic guidelines
Classic Hodgkin lymphoma (HL) is a distinct entity among hematological malignancies of B-cell origin. It is characterized by its unique histopathological features and generally favorable prognosis. Over the years, advancements in understanding its pathogenesis, coupled with refined diagnostic and evaluation modalities, as well as therapeutic strategies, have significantly transformed the landscape of HL management. In this article, we present a comprehensive set of recommendations for the management of HL, encompassing various aspects of diagnosis, risk stratification, evaluation, and treatment. These recommendations are based on the latest evidence-based guidelines, expert consensus opinions, and clinical trial data, aiming to provide clinicians with a practical framework for delivering optimal care to patients with HL.
期刊介绍:
The European Journal of Cancer (EJC) serves as a comprehensive platform integrating preclinical, digital, translational, and clinical research across the spectrum of cancer. From epidemiology, carcinogenesis, and biology to groundbreaking innovations in cancer treatment and patient care, the journal covers a wide array of topics. We publish original research, reviews, previews, editorial comments, and correspondence, fostering dialogue and advancement in the fight against cancer. Join us in our mission to drive progress and improve outcomes in cancer research and patient care.